Rezolute Past Earnings Performance
Past criteria checks 0/6
Rezolute's earnings have been declining at an average annual rate of -24.2%, while the Biotechs industry saw earnings growing at 19.1% annually.
Key information
-24.2%
Earnings growth rate
45.0%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -61.1% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
We Think Rezolute (NASDAQ:RZLT) Needs To Drive Business Growth Carefully
May 22
Rezolute, Inc. (NASDAQ:RZLT) Shares Could Be 31% Above Their Intrinsic Value Estimate
Feb 13Rezolute, Inc.'s (NASDAQ:RZLT) Intrinsic Value Is Potentially 65% Above Its Share Price
Sep 21Here's Why We're Watching Rezolute's (NASDAQ:RZLT) Cash Burn Situation
Jul 25We Think Rezolute (NASDAQ:RZLT) Can Afford To Drive Business Growth
Jan 31Rezolute GAAP EPS of -$0.37
Sep 15We're Keeping An Eye On Rezolute's (NASDAQ:RZLT) Cash Burn Rate
May 06Rezolute shares rise on positive topline results from RZ402 eye disease trial
May 04What Type Of Shareholders Make Up Rezolute, Inc.'s (NASDAQ:RZLT) Share Registry?
Jan 12Revenue & Expenses Breakdown
How Rezolute makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -69 | 16 | 56 |
| 30 Jun 24 | 0 | -68 | 15 | 55 |
| 31 Mar 24 | 0 | -58 | 14 | 47 |
| 31 Dec 23 | 0 | -57 | 14 | 49 |
| 30 Sep 23 | 0 | -56 | 14 | 48 |
| 30 Jun 23 | 0 | -52 | 13 | 43 |
| 31 Mar 23 | 0 | -48 | 12 | 41 |
| 31 Dec 22 | 0 | -44 | 11 | 36 |
| 30 Sep 22 | 0 | -43 | 10 | 34 |
| 30 Jun 22 | 0 | -41 | 10 | 32 |
| 31 Mar 22 | 0 | -38 | 9 | 28 |
| 31 Dec 21 | 0 | -31 | 9 | 23 |
| 30 Sep 21 | 0 | -25 | 9 | 18 |
| 30 Jun 21 | 0 | -21 | 8 | 15 |
| 31 Mar 21 | 0 | -18 | 7 | 13 |
| 31 Dec 20 | 0 | -19 | 6 | 13 |
| 30 Sep 20 | 0 | -19 | 5 | 14 |
| 30 Jun 20 | 0 | -20 | 6 | 14 |
| 31 Mar 20 | 0 | -20 | 6 | 14 |
| 31 Dec 19 | 0 | -37 | 7 | 25 |
| 30 Sep 19 | 0 | -34 | 7 | 21 |
| 30 Jun 19 | 0 | -33 | 7 | 19 |
| 31 Mar 19 | 0 | -42 | 7 | 24 |
| 31 Dec 18 | 0 | -25 | 8 | 12 |
| 30 Sep 18 | 0 | -27 | 8 | 14 |
| 30 Jun 18 | 0 | -30 | 9 | 17 |
| 31 Mar 18 | 0 | -24 | 10 | 13 |
| 31 Dec 17 | 0 | -27 | 9 | 14 |
| 30 Sep 17 | 0 | -27 | 9 | 14 |
| 30 Jun 17 | 0 | -24 | 8 | 12 |
| 31 Mar 17 | 0 | -27 | 6 | 12 |
| 31 Dec 16 | 0 | -22 | 5 | 11 |
| 30 Sep 16 | 0 | -21 | 5 | 10 |
| 30 Jun 16 | 0 | -21 | 5 | 9 |
| 31 Mar 16 | 0 | -14 | 5 | 9 |
| 31 Dec 15 | 0 | -14 | 5 | 8 |
| 30 Sep 15 | 0 | -12 | 5 | 7 |
| 30 Jun 15 | 0 | -11 | 6 | 5 |
| 31 Mar 15 | 0 | -10 | 6 | 3 |
| 31 Dec 14 | 0 | -12 | 7 | 2 |
| 30 Sep 14 | 0 | -11 | 6 | 0 |
| 30 Jun 14 | 0 | -10 | 5 | 0 |
| 31 Mar 14 | 0 | -9 | 4 | 0 |
Quality Earnings: RZLT is currently unprofitable.
Growing Profit Margin: RZLT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RZLT is unprofitable, and losses have increased over the past 5 years at a rate of 24.2% per year.
Accelerating Growth: Unable to compare RZLT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RZLT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: RZLT has a negative Return on Equity (-61.1%), as it is currently unprofitable.